Jennifer J. Knox

Research interests

Publications

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00469-2

• Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2021.01.220

• Spatially confined sub-tumor microenvironments in pancreatic cancer

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.09.022

• GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

  Clinical Cancer Research · 2020 · https://doi.org/10.1158/1078-0432.ccr-19-3724

• Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

  JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.4564

• A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer

  Clinical Cancer Research · 2020 · https://doi.org/10.1158/1078-0432.ccr-19-2803

• Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-019-0566-9

• A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

  British Journal of Cancer · 2019 · https://doi.org/10.1038/s41416-019-0474-x

• Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

  Cancer Cell · 2019 · https://doi.org/10.1016/j.ccell.2018.12.010

• Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.01307

• Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.2019.37.15_suppl.4004

• Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-1543

• Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0349

• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30146-3

• Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30351-6

• Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

  Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-17-2994

• Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

  Genome Medicine · 2016 · https://doi.org/10.1186/s13073-016-0364-2

• The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71222-7

• Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy

  European Urology · 2013 · https://doi.org/10.1016/j.eururo.2013.08.012

• Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.4809

• Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.15.9947

• Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.51.008

Current projects

No projects listed.